Loading data for ALLO — first visit, this takes a few seconds.
Allogene Therapeutics Inc... (ALLO)
NasdaqGS: ALLO
· Real-Time Price · USD
2.09
+0.05 (2.45%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Allogene Therapeutics Inc. (ALLO) Stock Price, Analysis & Data
2.45% (1D)
| Bid | 2.09 |
| Market Cap | 722.08M |
| Revenue (ttm) | 4.64M |
| Net Income (ttm) | -165.49M |
| 0.47 | |
| -0.66 | |
| n/a | |
| -2.98 | |
| P/B (ttm) | 1.65 |
| P/S (ttm) | 155.62 |
| Earnings Date | Nov 5, 2026 |
| Ask | 2.59 |
| Volume | 4,964,253 |
| Avg. Volume (20D) | 7,787,382 |
| Open | 2.03 |
| Previous Close | 2.04 |
| Day's Range | 2.00 - 2.14 |
| 52-Week Range | 1.04 - 4.46 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansege...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2018
Employees 150
Stock Exchange NasdaqGS
Ticker Symbol ALLO
Website https://allogene.com
Financial Performance
In 2025, Allogene Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 22K. Earnings were -190.89M, a decrease of -25.9%.
Financial StatementsEarnings Surprise
Allogene Therapeutics has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.13 exceeds estimates by 0.02, with 40.91% YoY growth.
Allogene Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2